Neuroprotection / Memory and neuroinflammation
MOTS-c Neuroprotection and Cognition Research
Two specimens on one tray: a mouse memory result with a cell-penetrating analogue, and a human multiple-sclerosis serum biomarker — set beside an equal-weight note that no human interventional brain data exist.
In plain English
This page covers MOTS-c neuroprotection — the research on whether MOTS-c protects the brain. "Neuroprotection" just means shielding nerve cells from damage. So far the evidence is thin and early. In mice, a redesigned version of MOTS-c built to cross into the brain improved memory and calmed brain inflammation in models of Alzheimer-type damage [5]. In people, one small study found that natural MOTS-c levels in blood differed between multiple sclerosis patients and healthy controls [6]. No trial has given MOTS-c to people to protect their brains. Read this as a promising lead, not a proven effect.
The mouse memory result
The central neuroprotection finding is a 2021 study in ACS Chemical Neuroscience. A cell-penetrating MOTS-c analogue — a version chemically modified so it can cross cell membranes and reach the brain after peripheral injection — enhanced memory and attenuated memory impairment induced by amyloid-beta(1-42) or LPS in mice, and it did so by inhibiting neuroinflammation [5]. Amyloid-beta(1-42) is the protein fragment that aggregates in Alzheimer's disease; LPS (lipopolysaccharide) is a bacterial molecule used experimentally to trigger inflammation [5].
Two qualifications matter. First, this used an engineered analogue, not native MOTS-c — native MOTS-c is a small unmodified peptide not optimised for brain delivery [5]. Second, the model is a mouse memory-impairment paradigm, not a human cognitive trial. The result is mechanistically coherent — MOTS-c's AMPK and antioxidant-stress biology plausibly intersects neuroinflammation [3][4] — but it is a single preclinical study.
Has MOTS-c Been Studied for Memory or Brain Health?
A cell-penetrating MOTS-c analogue given peripherally enhanced memory and attenuated amyloid-beta(1-42)- or LPS-induced memory impairment by inhibiting neuroinflammation in mice [5]. In humans, an exploratory study found serum MOTS-c differed between multiple sclerosis patients and controls [6]. All neuro evidence is preclinical or observational.
The human multiple-sclerosis biomarker
The only human neuro-relevant data is observational. A 2022 study in Cureus compared serum MOTS-c levels in patients with multiple sclerosis against healthy controls and found the levels differed between the groups [6]. Multiple sclerosis is a neuroinflammatory disease in which the immune system attacks the myelin coating of nerves.
This is an association in endogenous MOTS-c — the peptide these patients already produce — not a test of giving MOTS-c as a treatment [6]. It suggests MOTS-c may track with neuroinflammatory disease state; it does not show that administering MOTS-c changes that state. It is a single small exploratory study and awaits replication.
The broader mechanistic rationale connects to MOTS-c's NRF2 and antioxidant-response biology: under stress, MOTS-c regulates antioxidant genes, and oxidative stress and neuroinflammation are linked in neurodegeneration [3][4]. That makes neuroprotection a reasonable hypothesis to pursue — which is precisely its current status.
What is not shown
No completed human interventional trial has tested whether exogenous MOTS-c, native or analogue, protects the brain, improves cognition, or treats any neurological condition [5][6]. The mouse memory result and the human MS biomarker sit on the same tray as that gap — they are leads, not endpoints.
There is also no validated human pharmacokinetics for any MOTS-c form, and the brain-delivery problem is non-trivial: native MOTS-c is not built to cross the blood-brain barrier, which is why the memory study required an engineered cell-penetrating analogue [5]. Claims that MOTS-c is an established neuroprotective or nootropic agent in humans go well beyond this evidence. For the regulatory picture, see MOTS-c legal status; for sourcing and safety caveats, see the frequently asked questions.